Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Poznan University of Life Sciences | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to verify the effect of acute caffeine (CAF) and placebo (PLA) supplementation on physical capacity and discipline-specific exercise performance in athletes, in a randomised, double-blind, placebo-controlled crossover trial.
Caffeine (CAF) is often proposed as an ergogenic agent, especially during high-intensity efforts. CAF supplementation may reduce effort-induced multi-faceted symptoms of fatigue and can improve psychomotor functions (like agility or decision-making processes), which is required during the intermittent high-intensity efforts in combat sports and speed-strength disciplines. Moreover, it is suggested that CAF treatment is associated with increased glycolytic activity during simulated or real training/competition bouts, which results in performance and physical capacity improvement.
However, there are hardly any data on the individual CAF-induced and dose-dependent changes in physical capacity and discipline-specific performance in combat sports and speed-strength disciplines. Therefore, the study aims to examine the effect of acute, different-dose CAF ingestion on physical capacity and discipline-specific performance in combat sports and speed-strength athletes, in a randomized, double-blind, placebo-controlled crossover trial.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Caffeine supplementation | Experimental | Group taking oral CAF (Caffeine) supplementation in a different-dose crossover regimen. |
|
| Placebo treatment | Placebo Comparator | Group taking oral supplementation with placebo. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Caffeine supplementation | Dietary Supplement | The experimental procedure for each athlete includes an acute CAF supplementation in a different-dose crossover regimen in order to assess whether the dose affects the actual physical capacity and discipline-specific exercise performance (doses: 3.0-, 6.0- and 9.0 mg/kg of body mass, respectively). CAF (pure pharmaceutical caffeine) will be administered in the dissolved form. On testing days, the supplements will be taken 70 min before physical and exercise capacity test session. Between the CAF and PLA or a PLA and CAF treatments, a minimum 7-day washout period will be introduced. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in discipline-specific exercise capacity after caffeine supplementation and placebo treatment | Assessment of the discipline-specific exercise capacity tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in caffeine and paraxanthine concencentrations in serum and saliva before and after caffeine supplementation and placebo treatment | Assessment of the caffeine and paraxanthine concencentrations (μg/mL), and paraxanthine/caffeine ratio in serum and saliva before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation. Additionally CYP1A2 enzyme activity was assessed by the determination of the mean time-corrected PRX/CAF RATIO in saliva. | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in reaction and motor time (Vienna Test System) after caffeine supplementation and placebo treatment | Assessment of the reaction and motor time (Vienna Test System) (ms) before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in postural stability indices (COP velocity, Vcop) (posturographic platform AccuGaitTM) (after caffeine supplementation and placebo treatment | Assessment of the postural stability indices (COP velocity, Vcop) (posturographic platform AccuGaitTM) (cm/s) before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in postural stability indices (area 95 percentile, Area95) (posturographic platform AccuGaitTM) after caffeine supplementation and placebo treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in sports training / competition activities after discipline-specific exercise tests | Assessment of the sports training / competition activities after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in white blood cells and hematological indices (red blood cells, RBC) count in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the leukocytes (neutrophils, monocytes, lymphocytes, neutrophils:lymphocytes ratio) and the hematological indices (red blood cells, RBC)(count/L) count in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Krzysztof Durkalec-Michalski, PhD | Department of Sports Dietetics, Poznan University of Physical Education, Poznan, Poland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Sports Dietetics, Poznan University of Physical Education | Poznan | Wielkopolska | 61-871 | Poland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39529054 | Derived | Glowka N, Malik J, Aniola J, Zawieja EE, Chmurzynska A, Durkalec-Michalski K. The effect of caffeine dose on caffeine and paraxanthine changes in serum and saliva and CYP1A2 enzyme activity in athletes: a randomized placebo-controlled crossover trial. Nutr Metab (Lond). 2024 Nov 11;21(1):90. doi: 10.1186/s12986-024-00863-3. | |
| 31488190 |
Not provided
Not provided
Shared data will be exclusively related to the level of recorded indicators, without personal data. The data obtained will be attached to scientific publications, depending on the requirements of the journal.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo treatment | Dietary Supplement | The experimental procedure for each athlete will include PLA supplementation. Placebo will be administered in the dissolved form. On testing days, the PLA will be taken 70 min before physical and exercise capacity test session. Between the PLA and CAF or a CAF and PLA treatments, a minimum 7-day washout period will be introduced. |
|
Assessment of the postural stability indices (area 95 percentile, Area95) (posturographic platform AccuGaitTM) (cm2) before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation |
| Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in rate of perceived exertion after discipline-specific exercise tests |
Assessment of the Borg Rating of Perceived Exertion (RPE) scale after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation |
| Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in heart rate during discipline-specific exercise tests | Assessment of the Heart Rate during and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Analysis of psychological state before and after caffeine supplementation and placebo | Assessment of psychological state by chosen questionnaires was carried out before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Analysis of macronutrients in diets before and after caffeine supplementation and placebo treatment | Assessment of the macronutrients in diets (g) was carried out before the execution of exercise protocols on each research visit | Baseline and during 1 day of acute CAF and PLA supplementation |
| Analysis of body composition (fat-free mass, fat mass) | Assessment of body composition (fat-free mass, fat mass) (kg) was carried out before the execution of exercise protocols on each research visit | Baseline and during 1 day of acute CAF and PLA supplementation |
| Analysis of body composition (total body water) | Assessment of body composition (total body water) (%) was carried out before the execution of exercise protocols on each research visit | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in lactate and pyruvate concentrations in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the lactate and pyruvate concentration (mmol/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Analysis of gene polymorphisms | Assessment of the chosen gene polymorphisms in saliva carried out at baseline | Baseline |
| Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in hematological indices (hemoglobin concentration, HGB) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the hematological indices (hemoglobin concentration, HGB) (mmol/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in hematological indices (hematocrit, HCT) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the hematological indices (hematocrit, HCT) (L/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in hematological indices (mean corpuscular volume, MCV; mean platelet volume, MPV) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the hematological indices (mean corpuscular volume, MCV; mean platelet volume, MPV) (fL) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in hematological indices (mean corpuscular hemoglobin mass, MCH) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the hematological indices (mean corpuscular hemoglobin mass, MCH) (fmol) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in hematological indices (mean corpuscular hemoglobin concentration, MCHC) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the hematological indices (mean corpuscular hemoglobin concentration, MCHC) (mmol/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in hematological indices (platelet count, PLT) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the hematological indices (platelet count, PLT) (count x 109/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in hematological indices (platelet hematocrit, PCT) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the hematological indices (platelet hematocrit, PCT) (cL/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in hematological indices (platelet distribution width, PDW; platelet large cell ratio, PLCR; red blood cells distribution width - coefficient of variation, RDW-C) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the hematological indices (platelet distribution width, PDW; platelet large cell ratio, PLCR; red blood cells distribution width - coefficient of variation, RDW-C) (%) in in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in hematological indices (red blood cells distribution width - standard deviation, RDW-S) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the hematological indices (red blood cells distribution width - standard deviation, RDW-S) (fL) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in nutritional status indices (concentration of urea and magnesium) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the nutritional status indices (concentration of urea and magnesium) (mmol/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in nutritional status indices (concentration of glucose, calcium and phosphorans) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the nutritional status indices (concentration of glucose, calcium and phosphorans) (mg/dL) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in muscle damage markers (concentration of creatine) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the muscle damage markers (concentration of creatine) (μmol/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Changes in muscle damage markers (activity of alanine aminotransferase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase)) in capillary blood before and after caffeine supplementation and placebo treatment | Assessment of the muscle damage markers (activity of alanine aminotransferase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase) (U/L) in capillary blood before and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation | Baseline and during 1 day of acute CAF and PLA supplementation |
| Durkalec-Michalski K, Nowaczyk PM, Glowka N, Grygiel A. Dose-dependent effect of caffeine supplementation on judo-specific performance and training activity: a randomized placebo-controlled crossover trial. J Int Soc Sports Nutr. 2019 Sep 5;16(1):38. doi: 10.1186/s12970-019-0305-8. |